Cyto-KIK TRIAL: CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib)
Cyto-KIK Trial: CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Sponsor: Exelixis and Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAS6927
U.S. Govt. ID: NCT04322955
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment. The study will also evaluate the changes that nivolumab and cabozantinib cause in the cells adjacent to the tumor in order to understand how the study medicines work and how cancer cells become resistant to these medicines.
Mark Stein, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have kidney cancer that has spread to other parts of your body and you have not received treatment for the kidney cancer? Yes No
Are you willing to undergo treatment including the surgical removal of your kidney? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator